These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21949843)

  • 1. Astrocyte-derived tissue transglutaminase interacts with fibronectin: a role in astrocyte adhesion and migration?
    van Strien ME; Brevé JJ; Fratantoni S; Schreurs MW; Bol JG; Jongenelen CA; Drukarch B; van Dam AM
    PLoS One; 2011; 6(9):e25037. PubMed ID: 21949843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appearance of tissue transglutaminase in astrocytes in multiple sclerosis lesions: a role in cell adhesion and migration?
    van Strien ME; Drukarch B; Bol JG; van der Valk P; van Horssen J; Gerritsen WH; Breve JJ; van Dam AM
    Brain Pathol; 2011 Jan; 21(1):44-54. PubMed ID: 20731658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue transglutaminase in astrocytes is enhanced by inflammatory mediators and is involved in the formation of fibronectin fibril-like structures.
    Espitia Pinzón N; Brevé JJP; Bol JGJM; Drukarch B; Baron W; van Dam AM
    J Neuroinflammation; 2017 Dec; 14(1):260. PubMed ID: 29282083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astrocyte-derived tissue Transglutaminase affects fibronectin deposition, but not aggregation, during cuprizone-induced demyelination.
    Espitia Pinzon N; Sanz-Morello B; Brevé JJ; Bol JG; Drukarch B; Bauer J; Baron W; van Dam AM
    Sci Rep; 2017 Jan; 7():40995. PubMed ID: 28128219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition or ablation of transglutaminase 2 impairs astrocyte migration.
    Monteagudo A; Ji C; Akbar A; Keillor JW; Johnson GVW
    Biochem Biophys Res Commun; 2017 Jan; 482(4):942-947. PubMed ID: 27899316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the minimum domain of the fibronectin binding site on transglutaminase 2 (TG2) and its importance in mediating signaling, adhesion, and migration in TG2-expressing cells.
    Soluri MF; Boccafoschi F; Cotella D; Moro L; Forestieri G; Autiero I; Cavallo L; Oliva R; Griffin M; Wang Z; Santoro C; Sblattero D
    FASEB J; 2019 Feb; 33(2):2327-2342. PubMed ID: 30285580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of astrocytic transglutaminase 2 improves injury outcomes.
    Monteagudo A; Feola J; Natola H; Ji C; Pröschel C; Johnson GVW
    Mol Cell Neurosci; 2018 Oct; 92():128-136. PubMed ID: 29969654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue transglutaminase in marmoset experimental multiple sclerosis: discrepancy between white and grey matter.
    Espitia Pinzon N; Stroo E; 't Hart BA; Bol JG; Drukarch B; Bauer J; van Dam AM
    PLoS One; 2014; 9(6):e100574. PubMed ID: 24959868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
    Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
    Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction.
    Yakubov B; Chen L; Belkin AM; Zhang S; Chelladurai B; Zhang ZY; Matei D
    PLoS One; 2014; 9(2):e89285. PubMed ID: 24586660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transglutaminase 2 strongly binds to an extracellular matrix component other than fibronectin via its second C-terminal beta-barrel domain.
    Stamnaes J; Cardoso I; Iversen R; Sollid LM
    FEBS J; 2016 Nov; 283(21):3994-4010. PubMed ID: 27685605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transglutaminase 2 has higher affinity for relaxed than for stretched fibronectin fibers.
    Selcuk K; Leitner A; Braun L; Le Blanc F; Pacak P; Pot S; Vogel V
    Matrix Biol; 2024 Jan; 125():113-132. PubMed ID: 38135164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transglutaminase-2 interaction with heparin: identification of a heparin binding site that regulates cell adhesion to fibronectin-transglutaminase-2 matrix.
    Lortat-Jacob H; Burhan I; Scarpellini A; Thomas A; Imberty A; Vivès RR; Johnson T; Gutierrez A; Verderio EA
    J Biol Chem; 2012 May; 287(22):18005-17. PubMed ID: 22442151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26.
    Kotsakis P; Wang Z; Collighan RJ; Griffin M
    Amino Acids; 2011 Oct; 41(4):909-21. PubMed ID: 21046178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin.
    Sima LE; Yakubov B; Zhang S; Condello S; Grigorescu AA; Nwani NG; Chen L; Schiltz GE; Arvanitis C; Zhang ZY; Matei D
    Mol Cancer Ther; 2019 Jun; 18(6):1057-1068. PubMed ID: 31015308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling.
    Wang Z; Collighan RJ; Pytel K; Rathbone DL; Li X; Griffin M
    J Biol Chem; 2012 Apr; 287(16):13063-83. PubMed ID: 22298777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling.
    Wang Z; Collighan RJ; Gross SR; Danen EH; Orend G; Telci D; Griffin M
    J Biol Chem; 2010 Dec; 285(51):40212-29. PubMed ID: 20929862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase.
    Satpathy M; Cao L; Pincheira R; Emerson R; Bigsby R; Nakshatri H; Matei D
    Cancer Res; 2007 Aug; 67(15):7194-202. PubMed ID: 17671187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase.
    Khanna M; Chelladurai B; Gavini A; Li L; Shao M; Courtney D; Turchi JJ; Matei D; Meroueh S
    Mol Cancer Ther; 2011 Apr; 10(4):626-36. PubMed ID: 21330459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A crucial sequence for transglutaminase type 2 extracellular trafficking in renal tubular epithelial cells lies in its N-terminal beta-sandwich domain.
    Chou CY; Streets AJ; Watson PF; Huang L; Verderio EA; Johnson TS
    J Biol Chem; 2011 Aug; 286(31):27825-35. PubMed ID: 21652693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.